Farms.com Home   News

Forecast - Lower egg prices, more chickens in 2024

By Farms.com

In its eagerly anticipated Chickens and Eggs report, the USDA presents a forecast that spells good news for the poultry industry in 2024. The report predicts a 1.4% rise in egg production, totaling 96 billion eggs, alongside a modest 1% increase in the chicken population, underscoring a potential for growth amidst the agricultural sector's broader struggles. 

This positive outlook arrives as the industry grapples with decreasing farm numbers and challenges such as the effects of high path avian influenza, which continues to impact poultry. Despite these obstacles, poultry stands out for its growth potential, contrasting with shrinking inventories in other protein sectors. 

With egg prices expected to drop to an average of $1.83 per dozen, consumers may find some relief at the grocery store. This forecast is crucial for market analysis and strategic planning, especially given the forthcoming farm bill, which aims to bolster the agricultural sector's resilience by providing crucial support to farmers. 

The significance of sustaining the agricultural industry cannot be overstated, with the report and the 2022 Census of Agriculture emphasizing the need for policies that ensure the continuity and prosperity of farming.  

As the sector faces transformative challenges, the focus on securing a stable, affordable food supply through the farm bill and other measures is vital for both the national economy and global food security.


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.